Pediatric and adolescent patients with upfront, completely resected HCC can be effectively treated without chemotherapy. LT should be considered for nonmetastatic HCC, especially in the context of pre-existing chronic liver disease, even when the tumor exceeds MC. Distinct pediatric selection criteria are needed to identify patients most suitable for LT.
INTRODUCTION
Hepatocellular carcinoma (HCC) represents the second most common type of malignant hepatic neoplasm in children, though only 0.5-1% of all HCC manifest before 20 years of age. 1 In adults, HCC typically occurs in the setting of pre-existing chronic liver disease induced cirrhosis, triggered most commonly by viral hepatitis, excessive alcohol ABBREVIATIONS: A1AT, alpha-1 antitrypsin deficiency; CCG, Children's Cancer Group; COG, Children's Oncology Group; EFS, event-free survival; HCC, hepatocellular carcinoma; LT, liver transplantation; MC, Milan criteria; MELD, Model for End-Stage Liver Disease; OS, overall survival; PELD, pediatric end-stage liver disease; PFIC2, progressive familial intrahepatic cholestasis type-2; POG, Pediatric Oncology Group intake, or autoimmune and nonalcoholic steatohepatitis. 2 In children and adolescents within the Western world, only 30% of HCC occurs in the context of an identifiable pre-existing chronic liver disease, including anatomic abnormalities (Abernethy, Fontan procedure, and biliary atresia), and genetic predispositions (Alagille syndrome, progressive familial intrahepatic cholestasis type-2 [PFIC2]).
The mainstay of treatment for HCC in children and adolescents remains complete surgical resection. However, HCC is often invasive or multifocal at diagnosis, rendering less than 30% amenable to surgical resection. 3, 4 Historically, as an adjunct to surgery, children and adolescents with HCC have been treated with intensive multi-agent chemotherapy regimens, 5, 6 with approximately 40% of children with HCC demonstrating chemotherapy response. The 5-year event-free survival (EFS) for pediatric HCC remains suboptimal at 20%, with a 5-year overall survival (OS) ranging from 13 to 28%. [7] [8] [9] However, the prognosis is favorable in patients with Evans stage I HCC. While international cooperative group protocols have all included adjuvant chemotherapy for stage I HCC, its role remains unknown. 8 Liver transplantation (LT) is an option for pediatric patients with unresectable localized disease or HCC in the setting of end-stage liver disease. [10] [11] [12] [13] [14] The Milan criteria (MC) for transplant selection were originally defined for adults with HCC in the setting of cirrhosis, to identify the subset of patients who were likely to have favorable transplant outcomes. Unfortunately, there are no prospectively validated patient selection criteria for LT in the pediatric population. Most pediatric cases fall outside of MC at diagnosis; several retrospective studies have shown favorable outcomes in children with HCC that exceed MC. 13, [15] [16] [17] We conducted a single institution, retrospective review to improve our understanding of upfront, completely resected (Evans stage I) HCC in children and adolescents treated without adjuvant chemotherapy.
METHODS
Following institutional review board approval, a retrospective analysis was performed of patients < 18 years of age with upfront, completely resected HCC treated at our institution between January 1, 2004 and December 31, 2015. Evans stage I HCC was defined as completely upfront resected tumors, without macroscopic or microscopic residual disease, lymph node involvement, or metastatic disease. Patients with localized disease who underwent LT upfront were considered to also be Evan's stage I. 8 TNM staging was also obtained as per the American Joint Committee on Cancer (AJCC) for HCC. 18 Demographics, pre-existing conditions, treatment, therapy-related morbidity, and outcomes were reviewed. Histopathology, radiographic, and surgical data were reviewed by a pathologist (A.G.), radiologist (A.J.T.), and surgeons (A.B., J.D.N., M.A., and G.T.) for accuracy and completeness.
Histopathology was classified according to WHO Classification of
Tumors of the Digestive System. 19 Computed tomography scan and/or magnetic resonance imaging obtained at diagnosis were reviewed to determine the size and number of liver lesions as well as the overall PRETEXT score, based on Children's Oncology Group (COG) modifications to the 2005 PRETEXT guidelines. 20 The Child-Pugh score, 21 pediatric end-stage liver disease (PELD) score (for children < 12 years), 22 and Model for End-Stage Liver Disease (MELD) score (for children ≥ 12 years) 23 were collected. MC were assessed for each patient who underwent LT. 24 
RESULTS

Patient characteristics
We identified 32 patients < 20 years of age diagnosed with HCC at our institution from 2004 to 2015. Sixteen underwent resection at diagnosis, of which thirteen had negative margins and were classified as Evans stage I. Of these 13 patients, one had Fanconi anemia and required reduced-intensity conditioning allogeneic stem cell transplantation for myelodysplastic syndrome 2 months after HCC tumor resection, leading to nononcologic death. The remaining 12 patients were included in subsequent analysis ( Table 1 
Histopathology and molecular features
Pathology review showed four patients with a cirrhotic liver (PFIC-2 = 2, A1AT = 1, and Alagille = 1), with moderate to well-differentiated 
Staging and risk factors
PRETEXT stages were I (2), II (8) , and IV (2) ( Table 1 were initially thought to be wd-hepatocellular adenomas, prior to ultimate transplantation.
Surgical treatment
MC and the transplant cohort
Five of the seven patients who underwent LT exceeded MC by imaging (Table 2) . Specifically, one patient had a solitary lesion > 5 cm and four others had more than three foci with the largest foci being greater than 3 cm. The rationale to transplant outside of MC varied among patients.
In two cases (Patient #2 and 5), there was concern for impending liver failure in the setting of a cirrhotic background liver secondary to preexisting liver disease. One of those two patients had biopsy-proven HCC prior to transplant, whereas the other had high-grade dysplastic nodules at biopsy but confirmed HCC at transplant. Patients #4, 6, and 8 were transplanted for aforementioned reasons. All three of these patients exceeded MC; however, in all three, HCC was only confirmed at the time of transplant, and each was previously diagnosed with hepatic adenomas (ß-catenin activated subtype) from pretransplant biopsies.
Treatment-related morbidity and outcomes
There were no complications related to nontransplant HCC resections (n = 5). Of those who underwent LT, two patients had postoperative biliary complications, both requiring re-operation. Patient #3, due to her age and size, received a deceased donor, left lateral section allograft procured during an in situ split. Despite performing an on-table cholangiogram to delineate biliary anatomy, the segmental duct was not identified and therefore not reconstructed at the time of transplant. As a result, a second surgery was needed to place this duct into continuity with the patient's dominant biliary reconstruction. Patient #5 likely developed a contained leak from the transplant hepaticojejunostomy, which created an inflammatory pseudocyst which then created a mass effect. The subsequent biliary obstruction required removal of the rind and revision of the biliary anastomosis. 
TA B L E 2 Milan criteria of patients with upfront completely resected HCC treated with liver transplantation
DISCUSSION
HCC is an aggressive hepatic neoplasm that is often chemoresistant, with a response rate of ∼20% in adults and 40% in children, suggesting underlying biological differences between pediatric and adult HCC. 7 Prior cooperative group studies included chemotherapy for in a neoadjuvant setting. 7 Subsequently, SIOPEL 2 and 3 evaluated whether therapy intensification with platinum-and doxorubicin-based chemotherapy would improve tumor resectability. 25 Upfront surgery was not used in these SIOPEL studies, making it impossible to assess for any impact of chemotherapy for otherwise initially resectable HCC.
Complete surgical resection, when possible, remains the cornerstone of HCC therapy and the best chance for cure regardless of age at diagnosis. The main goal of surgical resection is to remove all sites of disease while preserving liver function. In adults, the presence of cirrhosis makes complete hepatic resection harder in terms of preserving liver function and minimizing the risk of perioperative complications from portal hypertension. 26 Additionally, two-thirds of pediatric patients with HCC present with unresectable disease, and use of chemotherapy to improve resectability is often not successful. 4 In our cohort, using traditional POG/CCG/COG surgical standards that include upfront surgery for initially resectable HCC when feasible, two patients underwent hepatic segmentectomy and three underwent hemihepatectomy ( Table 1 ). All five patients had a successful gross total resection, with negative margins, and remain disease free.
Despite extensive studies, the optimal liver resection margin remains controversial. Some studies have shown a resection margin of ≥2 cm to improve OS and recurrence 27, 28 while others have shown similar outcomes with a narrow margin of <1 cm or even <5 mm. 29, 30 In our cohort, one patient with 3 mm margins (Patient #10) received two cycles of adjuvant chemotherapy based on the discretion of the primary oncologist, and another with a 1 cm margin received six cycles of sorafenib due to intrabiliary and lymphovascular invasion (Patient #12). The other three patients who underwent conventional resection had 1.5-2 cm margins. With relatively small numbers, it is impossible to make conclusions on how to define adequate margins; however, we do note that all five patients, including two with ≤1 cm margins, are alive without recurrence.
LT in adult patients with HCC in whom surgical resection is not feasible has been shown to improve survival. 24, 31 In children with HCC, LT has been associated with improved disease-free survival (range = 63-89%) compared to conventional treatment with chemotherapy and resection, particularly in children with advancedstage tumors or chronic underlying liver disease. [10] [11] [12] [13] [14] [15] 32 The Pediatric Liver Unresectable Tumor Observatory registry was initiated to collect prospective data on pediatric patients (age < 18 years) undergoing LT for treatment of unresectable primary malignant liver tumors. 33 An interim report from 2015 included 53 patients with HCC who received an LT (29 with underlying genetic predisposition and 24 in the setting of a normal background liver). 34 The median follow-up = 799 days). 34 In pediatric patients who developed unresectable HCC without any chronic underlying disease, the results of LT were less favorable but cure was still observed in two-thirds of the cases (n = 24, median follow-up = 799 days). 34 In 1996, a prospective series of 48 adult patients with HCC with relatively small tumor masses (defined by size and number) and no extrahepatic or vascular extension demonstrated good transplant outcomes, leading to the generation of the MC, 24 a tool that has since been validated both retrospectively and prospectively. 24, 35 Using this criteria, long-term recurrence-free survival after LT in adult recipients with HCC has improved from 30% to 75%. 24, 35, 36 However, the MC have been criticized as being too strict; several studies have demonstrated good outcomes with more liberal criteria. [37] [38] [39] [40] The role of MC in the pediatric population has not been validated. A retrospective review of pediatric patients with HCC treated with LT (n = 11)
reported an OS of 73% in the transplant group compared to 50% of patients in the conventional group (n = 8) who were treated with liver resection ± chemotherapy (excluding two patients in the conventional group who had disseminated disease and did not receive any therapy due to poor general condition). Eight (73%) patients in the transplant group exceeded MC. 11 Another single-institution experience with LT in 10 children with HCC, in which 70% exceeded MC, demonstrated a 5-year OS of 83.3%. 15 Several additional studies have continued to demonstrate good transplant outcomes in children with HCC who exceed MC, highlighting the need for distinct pediatric criteria. 13, 17, 32 In our study, 71% (5/7) of patients that were transplanted exceeded the original MC (Table 2) , and all seven remain alive and cancer free.
A consideration in interpreting these data is that three of the patients exceeding MC were not known to have HCC at the time of transplant.
One reason why MC may not help appropriately select the best pediatric transplant candidates perhaps relates to underlying liver pathology. Specifically, MC were defined in adult patients with cirrhosis-associated HCC, whereas about 60-70% of pediatric HCC are reported to occur within a noncirrhotic liver. 2 Interestingly, a review of 105 adults who received an LT for noncirrhotic HCC demonstrated that, in contrast to HCC in cirrhosis, tumor size was not predictive of survival. 41 Secondly, the application of adult MC to children and adolescents undermines tumor biologic differences between the groups. As evidenced in the cohort presented herein, the biological heterogeneity of pediatric HCC is substantial. Of note, our cohort did have a higher number of patients with a predisposition to HCC (67%) compared to the typical incidence in North America (30%). For these reasons and based on evolving survival data, recent critical reviews of the management of advanced pediatric liver tumors advocate that LT should be offered to children with any size or number of HCC, provided there is no satisfactory surgical alternative and that the tumor remains confined to the liver. 17, 42 This retrospective case series is limited by its representation of a single institution with a quaternary hepatology and liver transplant program, thereby restricting its generalizability. Additionally, patient selection protocols may vary from one transplant center to another, which may lead to notable differences in outcomes. Given the small number of patients and absence of any events, we were unable to perform any analysis to identify risk factors associated with tumor recurrence.
In conclusion, complete tumor resection is essential for cure of pediatric and adolescent HCC. When complete upfront resection is achieved, especially for patients with underlying conditions predisposing to HCC, adjuvant chemotherapy can likely be omitted. Early consideration of LT may be beneficial to children and adolescents with unresectable localized disease, possibly independent of MC, provided that the disease remains confined to the liver. Given the rarity of these tumors in children and adolescents, national and international collaboration is essential to prospectively validate our results on a larger scale, to facilitate evaluation of novel therapeutic approaches, to improve our understanding of biological differences between pediatric and adult HCC, and to further define distinct algorithmic care specific for pediatric and adolescent HCC.
